DOI: https://doi.org/10.18370/2309-4117.2020.56.18-22

From menarche to menopause

T. F. Tatarchuk

Abstract


On September 11–12, 2020, in Kyiv hosted the International Women's Health Summit “From Menarche to Menopause” with the participation of leading foreign and domestic experts in the field of obstetrics and gynecology. The event was devoted to such topical topics as miscarriage, infertility, menstrual irregularities, menopausal hormone therapy (MHT).

The current concern in clinical practice is not overuse of MHT, but it underutilization, and the fact that only a small number of women with impaired quality of life through menopausal symptoms receive treatment, despite that they perfectly fit the patient's profile for such therapy.

All types of MHT are characterized by following effects: a positive effect on the cardiovascular system if MHT was start before 60 ages or in the first 10 years after menopause onset; the mortality rate from all causes is not increased in patients on MHT. The “ideal” MHT should relieve vasomotor symptoms, influence urogenital symptoms, prevent fractures and bone loss, protect the cardiovascular system and endometrium, and should not increase the risks of breast cancer, deep vein thrombosis and pulmonary embolism. Estradiol + dydrogesterone (Femoston®) scheme fits perfectly into these criteria. Femoston® is an oral MHT preparation that is effective in relieving symptoms of estrogen deficiency with a proven safety profile on the cardiovascular system and breast. This drug helps to reduce the manifestations of symptoms of estrogen deficiency, increase bone mineral density, and has a positive effect on metabolic processes. Numerous studies have shown that combination of estradiol + dydrogesterone is not only highly effective against menopausal symptoms, but also extremely important features, in particular, a proven safety profile for breast cancer.


Keywords


summit; menopause; menopausal hormone therapy; estradiol; dydrogesterone; Femoston

References


United Nations Department of Economic and Social Affairs: Population Division. Ukrainian population in 2020. Available from: [https://countrymeters.info/ru/Ukraine], last accessed Dec 12, 2020.

Rossouw, J.E., Anderson, G.L., Prentice, R.L., et al. “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial.” JAMA 288.3 (2002): 321–33.

Instruction for medical use of FEMOSTON® drug 1/10, 2/10 from 01.23.2017.

Instruction for medical use of FEMOSTON® CONTI drug from 01.23.2017.

Instruction for medical use of FEMOSTON® CONTI MINI drug from 03.21.2019.

Cieraad, D., Conradt, C., Jesinger, D., Bakowski, M. “Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.” Arch Gynecol Obstet 274.2 (2006): 74–80. DOI: 10.1007/s00404-006-0132-4

Lees, B., et al. “The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17β and dydrogesterone.” Osteoporosis Int 12 (2001): 251–8.

Godsland, I.F., Manassiev, N.A., Felton, C.V., et al. “Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.” Clin Endocrinol (Oxf) 60.5 (2004): 541–9. DOI: 10.1111/j.1365-2265.2004.02017.x

Schneider, C., Jick, S.S., Meier, C.R. “Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations.” Climacteric 12.5 (2009): 445–53. DOI: 10.1080/13697130902780853

Canonico, M., Oger, E., Plu-Bureau, G., et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. “Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.” Circulation 115.7 (2007): 840–5. DOI: 10.1161/CIRCULATIONAHA.106.642280

Lyytinen, H., et al. “Breast cancer risk in postmenopausal women using estradiol-progestogen therapy.” Obst Gyn 113 (2009): 65–73.

Fournier, A., et al. “Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.” Breast Cancer Res Treat 107 (2008): 103–11.

National Comprehensive Cancer Network. NCCN guidelines for detection, prevention, & risk reduction. Available from: [https://www.nccn.org/professionals/physician_gls/default.aspx#detection], last accessed Dec 12, 2020.

European Society for Medical Oncology. Guidelines. Available from: [https://www.esmo.org/guidelines], last accessed Dec 12, 2020.

Santen, R.J., Mansel, R. “Benign breast disorders.” N Engl J Med 353.3 (2005): 275–85. DOI: 10.1056/NEJMra035692

International Menopause Society. Available from: [https://www.imsociety.org/], last accessed Dec 12, 2020.

Australian Menopause Society. Available from: [https://www.menopause.org.au/], last accessed Dec 12, 2020.

Shestakova, I. G. “Influence of hormone replacement therapy with Femoston on body weight and carbohydrate metabolism in perimenopausal women.” Problems of reproduction 2 (2001): 46–8.

Schindler, A.E., Campagnoli, C., Druckmann, R., et al. “Classification and pharmacology of progestins.” Maturitas 61.1–2 (2008): 171–80. DOI: 10.1016/j.maturitas.2008.11.013

Amy, J.J. “Femoston®: Effects on bone and quality-of-life.” Eur Menop J 2 (Suppl) (1995): 16–22.


GOST Style Citations


1.         Департамент по экономическим и социальным вопросам ООН: Отдел народонаселения.Население Украины в 2020 г.

2.         Rossouw, J.E., Anderson, G.L., Prentice, R.L., et al. “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial.” JAMA 288.3 (2002): 321–33.

3.         Інструкція для медичного застосування лікарського засобу ФЕМОСТОН® 1/10, 2/10 від  23.01.2017.

4.         Інструкція для медичного застосування лікарського засобу ФЕМОСТОН® КОНТІ від 23.01.2017.

5.         Інструкція для медичного застосування лікарського засобу ФЕМОСТОН® КОНТІ МІНІ від 21.03.2019.

6.         Cieraad, D., Conradt, C., Jesinger, D., Bakowski, M. “Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.” Arch Gynecol Obstet 274.2 (2006): 74–80. DOI: 10.1007/s00404-006-0132-4

7.            Lees, B., et al. “The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17β and dydrogesterone.” Osteoporosis Int 12 (2001): 251–8.

8.            Godsland, I.F., Manassiev, N.A., Felton, C.V., et al. “Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.” Clin Endocrinol (Oxf) 60.5 (2004): 541–9. DOI: 10.1111/j.1365-2265.2004.02017.x

9.            Schneider, C., Jick, S.S., Meier, C.R. “Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations.” Climacteric 12.5 (2009): 445–53. DOI: 10.1080/13697130902780853

10.          Canonico, M., Oger, E., Plu-Bureau, G., et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. “Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.” Circulation 115.7 (2007): 840–5. DOI: 10.1161/CIRCULATIONAHA.106.642280

11.          Lyytinen, H., et al. “Breast cancer risk in postmenopausal women using estradiol-progestogen therapy.” Obst Gyn 113 (2009): 65–73.

12.          Fournier, A., et al. “Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.” Breast Cancer Res Treat 107 (2008): 103–11.

13.          National Comprehensive Cancer Network. NCCN guidelines for detection, prevention, & risk reduction. Available from: [https://www.nccn.org/professionals/physician_gls/default.aspx#detection], last accessed Dec 12, 2020.

14.          European Society for Medical Oncology. Guidelines. Available from: [https://www.esmo.org/guidelines], last accessed Dec 12, 2020.

15.          Santen, R.J., Mansel, R. “Benign breast disorders.” N Engl J Med 353.3 (2005): 275–85. DOI: 10.1056/NEJMra035692

16.          International Menopause Society. Available from: [https://www.imsociety.org/], last accessed Dec 12, 2020.

17.          Australian Menopause Society. Available from: [https://www.menopause.org.au/], last accessed Dec 12, 2020.

18.          Шестакова, И.Г. Влияние заместительной гормональной терапии препаратом Фемостон на массу тела и углеводный обмен у женщин в перименопаузе / И.Г. Шестакова // Проблемы репродукции. – 2001. – № 2. – С. 46–48.

19. Schindler, A.E., Campagnoli, C., Druckmann, R., et al. “Classification and pharmacology of progestins.” Maturitas 61.1–2 (2008): 171–80. DOI: 10.1016/j.maturitas.2008.11.013

20. Amy, J.J. “Femoston®: Effects on bone and quality-of-life.” Eur Menop J 2 (Suppl) (1995): 16–22.





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)